How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses

Blood

Volumn 126, Issue 15, 2015, Pages 1860-1861

  Prasad, Vinay ^a,b   Mailankody, Sham ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; IMATINIB; IRINOTECAN; OXALIPLATIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

CANCER REGRESSION; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; EXPERIMENTAL THERAPY; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LETTER; ONCOLOGY; PRIORITY JOURNAL; ECONOMICS; HEMATOLOGIC NEOPLASMS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS;

EID: 84943599112     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-07-657478     Document Type: Letter

References (8)

1. Saret CJ, Winn AN, Shah G, et al. Value of innovation in hematologic malignancies: A systematic review of published cost-effectiveness analyses. Blood. 2015;125(12):1866-1869.
2. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332(7543):699-703.
3. Hayslip JW, Simpson KN. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma. 2008;8(3):166-170.
4. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108(10):3295-3301.
5. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853-2858.
6. Asseburg C, Frank M, Köhne CH, et al. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Clin Ther. 2011;33(4):482-497.
7. Schrag D, Dueck AC, Naughton MJ, et al. Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: economic analysis of CALGB/SWOG 80405 [abstract]. J Clin Oncol. 2015;33(15 suppl). Abstract 6504.
8. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. NBER Working Paper Series. Working Paper 20867. Cambridge, MA: National Bureau of Economic Research; 2015.